FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer


5 August 2022 - On 5 August 2022, the FDA approved darolutamide (Nubeqa, Bayer) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

Efficacy was based on ARASENS, a randomised, multi-centre, double-blind, placebo-controlled clinical trial in 1306 patients with metastatic hormone-sensitive prostate cancer.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US